Arcus Biosciences (RCUS) Accounts Payables (2017 - 2026)

Arcus Biosciences' Accounts Payables history runs 10 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 77.27% year-over-year to $39.0 million in Q1 2026; TTM through Mar 2026 was $39.0 million, a 77.27% increase from a year earlier, with the FY2025 full-year figure at $42.0 million, up 133.33% from the prior year.
• Accounts Payables eased to $39.0 million in Q1 2026 per RCUS's latest filing, from $42.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $42.0 million in Q3 2025 and bottomed at $10.5 million in Q3 2022.
• The 5-year median for Accounts Payables is $18.1 million (2022), against an average of $22.4 million.
• Across the five-year window, Accounts Payables plunged 45.41% in 2023 and surged 223.08% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $20.0 million in 2022, then retreated by 15.0% to $17.0 million in 2023, then climbed by 5.88% to $18.0 million in 2024, then jumped by 133.33% to $42.0 million in 2025, then decreased by 7.14% to $39.0 million in 2026.
• Per Business Quant, the three latest RCUS Accounts Payables figures stand at $39.0 million (Q1 2026), $42.0 million (Q4 2025), and $42.0 million (Q3 2025).